Scholars Central

Short communicationPublished 23 Jan 2021

An Overview on SARSCoV-2

Authors: Jaya Keerthi

Translational Medicine

Volume 11 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A Novel Covid (named 2019-nCoV) was accounted for in December 2019 from genomic screening of clinical examples from patients with viral pneumonia in Wuhan, China. The essential viral pneumonia patients were discovered to be epidemiologically connected to the Huanan fish market in Wuhan City, Hubei Province, China, where other non-oceanic creatures, for example, bats, pangolins and bunnies, were at a bargain before the episode. Using cutting edge sequencing, another, human tainting Covid, temporarily called 2019 novel Covid (2019-nCoV), was recognized. Thusly, on February 11, 2020, episode or illness recently known as "novel Covid" or 2019-nCoV was formally renamed as C-O-V-I-D-19 or COVID-19 and causal infection was named as “Severe acute respiratory syndrome-related coronavirus 2” or SARSCoV-2

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Translational Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTranslational Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Jaya Keerthi”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels